BLOG/πŸ‡ΊπŸ‡ΈUnited StatesΒ·Β·daily

S&P 500 Technology Sector SEC Filings β€” March 26, 2026

USA S&P 500 Technology

7 high priority6 medium priority13 total filings analysed

Executive Summary

Across 13 filings from the S&P 500 Technology stream (with some cross-sector inclusions), dominant themes include neutral proxy statements for upcoming AGMs, mixed financial results highlighting cost discipline amid revenue softness, and selective growth in reserves/operations. Period-over-period trends show revenue declines averaging -5% YoY in reporting companies (e.g., Arcadia -4% FY2025, Q4 -26%), offset by operating expense cuts (Arcadia -15% FY, Mueller +24.4% op income YoY), with outliers like Mueller's record +10.9% sales and +26.5% net income. Critical developments: Mueller's 2030 plan targeting $1.5B op income, Arcadia's terminated deal and $2.1M cash infusion for growth, AParadise SPAC progress toward ENHA NYSE listing, and Canadian Natural's +4.5% proved reserves to 15,910 MMBOE. No insider trading activity reported across filings, limiting conviction signals; capital allocation shines with Mueller's $244M buybacks and 25% dividend hike. Portfolio implications: Tech exposure limited to stable Apple passive stake; monitor governance votes and May catalysts for alpha in industrials/biosciences proxies. Overall, cautious optimism from improving losses (+31-46% YoY in Arcadia) and strategic plans amid cash pressures.

Tracking the trend? Catch up on the prior S&P 500 Technology Sector SEC Filings digest from March 25, 2026.

Investment Signals(10)

  • Record 2025 net sales +10.9% YoY to $4.18B, op income +24.4% to $959M, EPS +29.2% to $6.86, $244M buybacks, 25% dividend increase to $1.00/share, zero debt, 2030 plan for $1.5B op income

  • Arcadia Biosciences (10-K/8-K)(BULLISH)
    β–²

    FY2025 op loss improved 31% YoY to $2.5M, net loss -46% to $2.3M ($1.71/share vs $5.17), op ex -15% YoY, cash use in ops -49%, $2.1M from option exercises for Zola growth

  • Proved reserves +4.5% YoY to 15,910 MMBOE via 760 MMBOE acquisitions/extensions, proved+probable at 20,750 MMBOE despite production deducts

  • AParadise Acquisition (SPAC)(BULLISH)
    β–²

    De-SPAC progress with S-4 updates post-SEC comments, $40M SAFE placement, Enhanced Games launch May 2026 with $25M prizes, YouTube streaming/broadcast talks

  • CFFO +16.9% YoY to $755M, FCF +21.4% to $687M, $1.39B cash, capex $68.8M disciplined vs growth

  • Zola product revenues +17% YoY by $701K on higher volume, strategic alternatives post-Roosevelt termination

  • Apple (Vanguard 13G/A)(BULLISH)
    β–²

    Stable passive ownership post-internal realignment, no control intent, confirms long-term holder status

  • Outperforms peers with +26.5% net income YoY to $765M despite residential/tariff headwinds

  • Radian Group↓(NEUTRAL-BULLISH)
    β–²

    Master Repurchase facility active for mortgage loan financing, terms stable post-2nd amendment

  • β–²

    Board declassification proposal for annual elections, enhancing governance

Risk Flags(8)

  • Arcadia Biosciences (10-K)[HIGH RISK]
    β–Ό

    Revenues -4% YoY FY2025 to $4.858M, license/royalty income -100%, cash drop to $259K from $4.2M, assets -52% to $6.5M

  • Arcadia Biosciences (8-K)[MEDIUM RISK]
    β–Ό

    Q4 revenues -26% YoY to $901K, FY cost of revenues +5% YoY despite Q4 -14%, cash used in ops persists

  • β–Ό

    Allowance for credit losses $559K (vs $0 prior), terminated business combo with Roosevelt

  • Radian Group↓[MEDIUM RISK]
    β–Ό

    Borrowing max cut to $25M from prior, signaling tighter liquidity/facility terms

  • North Sea reserves to 0 from 7 MMBOE, Offshore Africa -23% to 46 MMBOE, production deducts 573 MMBOE

  • β–Ό

    Working capital surplus down to $4.3M from $6.7M, short-term investments $4.3M new but cash burn $4.7M ops

  • β–Ό

    Weakened residential construction/international markets/tariffs noted despite record results

  • β–Ό

    No historical financials, reliance on forward-looking Enhanced Games/media rights

Opportunities(8)

Sector Themes(6)

  • Cost Discipline Amid Revenue Softness
    β—†

    2/3 financial reporters (Arcadia filings) show op ex cuts -15-35% driving loss improvements +31-46% YoY despite rev -4-26%, implying margin expansion potential vs peers [IMPLICATION: Buy cost-cutters]

  • Capital Allocation Strength in Outliers
    β—†

    Mueller leads with $244M buybacks/25% div hike/zero debt vs Arcadia cash burn; aggregate buyback/div trends favor industrials over biosciences [IMPLICATION: Favor return-focused names]

  • Reserve/Asset Growth Selective
    β—†

    Canadian +4.5% reserves YoY, Arcadia assets -52%; no tech-wide pattern but acquisition-driven upside in resources [IMPLICATION: M&A monitors]

  • Governance Evolution via Proxies
    β—†

    5/13 filings (Murphy x2, Mueller, Optimum, etc.) propose declassification/special meetings, 4 AGMs May 2026; enhances shareholder rights [IMPLICATION: Activist catalysts]

  • Neutral Debt/Financing Activity
    β—†

    Radian facility cut, FHLB $123.5M bonds at 4.1-4.5%, routine but watch spreads for liquidity signals [IMPLICATION: Stable funding environment]

  • SPAC/Go-Public Momentum
    β—†

    AParadise S-4 progress, $40M raise; contrasts mature filers, forward-looking sports/tech convergence [IMPLICATION: High-beta listings]

Watch List(7)

Filing Analyses(13)
RADIAN GROUP INC8-Kneutralmateriality 6/10

26-03-2026

Radian Group Inc., through its subsidiary Radian Mortgage Capital LLC, entered into the Second Amendment to the Master Repurchase Agreement with Everbank Bank, N.A., dated March 23, 2026, decreasing the maximum borrowing amount to $25 million from prior levels. The facility finances the acquisition of residential mortgage loans for sale or securitization, with prior amendments since April 2025 updating pricing terms. All other terms of the original April 30, 2025 agreement and the Parent Guaranty remain unchanged.

  • Β·Original Master Repurchase Agreement dated April 30, 2025
  • Β·Second Amendment filed as Exhibit 10.1
Arcadia Biosciences, Inc.10-Kmixedmateriality 8/10

26-03-2026

Arcadia Biosciences reported total revenues of $4,858 thousand for the year ended December 31, 2025, down 4% YoY from $5,045 thousand, driven by a 3% decline in product revenues and the complete elimination of license and royalty income (-100% each). Operating expenses fell 15% to $7,358 thousand, resulting in a narrower loss from operations of $2,500 thousand (improved 31% YoY) and net loss from continuing operations of $2,339 thousand (46% improvement YoY), though cash and equivalents dropped to $259 thousand from $4,242 thousand amid $4,739 thousand cash used in operations. Total assets decreased to $6,546 thousand from $13,517 thousand, with working capital surplus at $4,297 thousand versus $6,679 thousand prior year.

  • Β·Allowance for credit loss on accounts receivable: $559 thousand as of Dec 31, 2025 (vs $0 in 2024)
  • Β·Short-term investments: $4,304 thousand as of Dec 31, 2025 (vs $0 in 2024)
  • Β·Gain on sale of intangible assets: $750 thousand in 2025 (vs $4,000 thousand in 2024)
  • Β·Common stock warrant and option liabilities: $347 thousand as of Dec 31, 2025 (down from $2,731 thousand)
AParadise Acquisition Corp.425positivemateriality 8/10

26-03-2026

Enhanced is going public via a merger with SPAC A Paradise Acquisition Corp. (APAD, to trade as ENHA on NYSE), with the De-SPAC announced pre-Thanksgiving 2025 alongside a $40 million SAFE private placement; the S-4 filing recently updated reflects progress through SEC comments. The company operates sports competitions like the upcoming Enhanced Games with a $25 million prize pool for ~50 athletes (minimum $80K appearance fees, $500K per event), media/broadcast rights, and brand partnerships to drive its direct-to-consumer telehealth and supplements business (Live Enhanced). No historical financial performance data provided; focus is on forward-looking business model integrating athlete enhancements with consumer products.

  • Β·Enhanced Games to be streamed for free on YouTube, with talks for US broadcast in 80 million households
  • Β·Games event in ~2 months from March 2026 interview (May 2026), location Las Vegas implied for viewing
  • Β·Athletes receive holistic support including coaches, recovery facilities, nutritionists, physio, psychologists
CANADIAN NATURAL RESOURCES LTD40-Fmixedmateriality 9/10

26-03-2026

Canadian Natural Resources Ltd's Form 40-F annual filing reports total proved reserves of 15,910 MMBOE as of December 31, 2025, up 4.5% from 15,231 MMBOE at December 31, 2024, supported by acquisitions adding 760 MMBOE, extensions, infill drilling, and positive technical revisions of 300 MMBOE. However, North Sea proved reserves declined to zero from 7 MMBOE due to production and negative revisions, Offshore Africa reserves fell to 46 MMBOE from 60 MMBOE, and production deducted 573 MMBOE overall. Total proved plus probable reserves stood at 20,750 MMBOE, with a workforce of 10,750 employees.

  • Β·Acquisitions added 760 MMBOE to proved reserves
  • Β·Production deducted 573 MMBOE from proved reserves
  • Β·Total proved plus probable reserves: 20,750 MMBOE as of Dec 31, 2025
  • Β·North America employees: 3,068 in Exploration and Production; 4,970 in Oil Sands Mining and Upgrading
Arcadia Biosciences, Inc.8-Kmixedmateriality 8/10

26-03-2026

Arcadia Biosciences reported Q4 and FY 2025 financial results showing total revenues declining 26% YoY to $901 thousand in Q4 and 4% YoY to $4,858 thousand for the full year, despite Zola revenues increasing 17% YoY by $701 thousand driven by higher distribution volume. Operating expenses fell 35% in Q4 and 15% for FY, with SG&A down 27% and net cash used in operations down 49%, improving loss from continuing operations by 40% in Q4 and 31% FY, and net loss to $1.3 million ($0.97/share) in Q4 and $2.3 million ($1.71/share) FY. The company terminated its proposed business combination with Roosevelt Resources and received $2.1 million gross proceeds from the exercise of preferred investment options to support Zola growth and strategic alternatives.

  • Β·Cost of revenues decreased 14% in Q4 2025 YoY but increased 5% for FY 2025 YoY.
  • Β·Q4 2025 net loss $0.97 per share vs $2.98 prior year; FY 2025 $1.71 per share vs $5.17.
  • Β·Other operating expenses increased $1.2M FY 2025 due to absence of $4.0M Corteva gain in 2024, offset by $750K Bioceres gain and $2.0M contingent liability reduction in 2025.
  • Β·Q4 2024 revenues included $55K GLA oil sales absent in 2025; FY 2024 included $756K GLA oil sales absent in 2025.
Murphy USA Inc.DEF 14Aneutralmateriality 7/10

26-03-2026

Murphy USA Inc. filed its DEF 14A Proxy Statement on March 26, 2026, for the 2026 Annual Meeting of Stockholders on May 7, 2026, proposing the election of four Class I directors, ratification of the independent auditor for fiscal 2026, an advisory vote on 2025 executive compensation, amendments to declassify the board over time, and stockholder rights to call special meetings. A stockholder proposal also seeks to enable shareholders to call special meetings. The filing includes references to 2025 compensation tables and pay versus performance disclosures, with no operational financial metrics reported.

  • Β·Quorum requires majority of total voting power of outstanding shares.
  • Β·Proxy materials available at www.proxyvote.com.
  • Β·Proposals include Proposal 4 to phase-out board classification for annual elections and Proposal 5/6 on stockholder special meeting rights.
Murphy USA Inc.DEFA14Aneutralmateriality 8/10

26-03-2026

Murphy USA Inc. filed a DEFA14A proxy statement for its 2026 Annual Meeting on May 7, 2026, proposing the election of four Class I directors (Claiborne P. Deming, Hon. Jeanne L. Phillips, Jack T. Taylor, Michael G. Kulp), ratification of the independent auditor for Fiscal 2026, advisory approval of executive compensation, and amendments to declassify the board and enable shareholder-called special meetings, with the board recommending FOR on items 1-5. A stockholder proposal seeking shareholder ability to call special meetings is recommended AGAINST by the board. Proxy materials are available at www.ProxyVote.com, with voting deadlines of May 6, 2026 (or May 4 for plan shares).

  • Β·Meeting time: 8:00 AM Central Daylight Time at Murphy USA Corporate Headquarters, 200 East Peach Street, El Dorado, AR 71730
  • Β·Request proxy materials by April 23, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
  • Β·Control numbers: V85507-P47889-Z92261 and V85508-P47889-Z92261
MUELLER INDUSTRIES INCDEFA14Aneutralmateriality 4/10

26-03-2026

Mueller Industries, Inc. filed Definitive Additional Proxy Soliciting Materials (DEFA14A) on March 26, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing includes graphics such as checked/unchecked boxes and the company logo, likely intended to solicit shareholder votes or provide voting instructions. No financial metrics, performance data, or specific proposals are discernible in the provided content.

  • Β·Company address: Suite 100, 150 Schilling Boulevard, Collierville, TN 38017
  • Β·Fiscal year end: December 27
  • Β·State of incorporation: DE
  • Β·EIN: 250790410
  • Β·Former name: Sharon Steel Corp (changed January 3, 1991)
MUELLER INDUSTRIES INCDEF 14Apositivemateriality 8/10

26-03-2026

Mueller Industries delivered record 2025 results with net sales of $4.18B (up 10.9% YoY), operating income of $959M (up 24.4% YoY), net income of $765M (up 26.5% YoY), and diluted EPS of $6.86 (up 29.2% YoY) despite weakened residential construction, international markets, and tariff disruptions. Cash flow from operations reached $755M (up 16.9% YoY), free cash flow $687M (up 21.4% YoY), with $1.39B cash, zero debt, $244M stock repurchases, and a 25% dividend increase to $1.00 per share. The company launched its 2030 Strategic Plan targeting $1.5B operating income.

  • Β·Two-for-one stock split on October 20, 2023 (book value adjusted).
  • Β·Capital expenditures 2025: $68.8M.
  • Β·Annual meeting scheduled for May 7, 2026.
  • Β·Acquired Elkhart Products, Nehring, and Conex in 2024.
  • Β·Reshoring plumbing press fitting manufacturing to U.S., targeting substantial completion by end 2026.
MILLS MUSIC TRUST8-Kneutralmateriality 4/10

26-03-2026

Mills Music Trust filed an 8-K on March 26, 2026, disclosing under Item 8.01 that it issued a quarterly distribution report to unit holders on March 25, 2026, with computation details for payments received attributable to the fourth quarter of 2025. The full report is included as Exhibit 99.1. No specific financial metrics or performance comparisons were detailed in the filing body.

  • Β·Report pertains to payments for Q4 2025.
  • Β·Registrant address: C/O HSBC Bank USA, N.A., Corporate Trust Issuer Services, 66 Hudson Boulevard East, New York, New York 10001.
  • Β·No securities registered pursuant to Section 12(b) of the Act.
Federal Home Loan Bank of San Francisco8-Kneutralmateriality 6/10

26-03-2026

The Federal Home Loan Bank of San Francisco announced the issuance of consolidated obligation bonds for which it is the primary obligor, totaling $123.5 million in par value, with maturities in 2031 and fixed rates of 4.500% or 4.110%. These bonds were traded on March 23-24, 2026, with settlements in late March or early April 2026, and include optional principal redemption features. No declines or flat performance noted as this pertains to new debt issuances in the ordinary course of business.

  • Β·Bonds feature Optional Principal Redemption (Bermudan or European style), Fixed Constant rates of 4.500% (next call 3/25/2027) or 4.110% (next call 4/9/2029).
  • Β·Maturity dates: 3/25/2031 for most, 4/9/2031 for last.
  • Β·Regulated by Federal Housing Finance Agency; obligations backed by resources of eleven Federal Home Loan Banks, not U.S. government.
OptimumBank Holdings, Inc.DEF 14Aneutralmateriality 7/10

26-03-2026

OptimumBank Holdings, Inc. (OPHC) has issued a proxy statement for its 2026 Annual Meeting of Shareholders on April 28, 2026, seeking approval for electing six directors, amending the Articles of Incorporation to authorize a class of nonvoting common stock, ratifying Hacker, Johnson & Smith, P.A. as independent auditor for fiscal 2026, and potentially adjourning the meeting if needed. The record date is March 9, 2026, with 12,166,437 shares of common stock outstanding held by approximately 1,517 registered shareholders. The Board recommends voting FOR all proposals, with no financial performance metrics or period comparisons disclosed.

  • Β·Quorum requires majority of outstanding shares (at least 50% plus one share) present in person or by proxy.
  • Β·Proposal 1 (director election) requires plurality vote; Proposals 2-4 require majority of shares present or outstanding as specified.
  • Β·Internet voting deadline: 11:59 p.m. ET on April 27, 2026.
  • Β·Director nominees: Moishe Gubin (age 49, independent since 2010), Joel Klein (age 79, non-independent since 2012), Thomas Procelli (age 71, independent since 2017), Avi Zwelling (age 53, independent since 2017), Michael Blisko (age 50, independent since 2021), Steven Newman (age 49, independent since 2022).
Apple Inc.SCHEDULE 13G/Aneutralmateriality 6/10

26-03-2026

The Vanguard Group Inc. filed a Schedule 13G/A amendment for Apple Inc. on March 26, 2026, disclosing an internal realignment on January 12, 2026, under which certain subsidiaries will report beneficial ownership of Apple shares separately per SEC Release No. 34-39538. The filing confirms Vanguard's passive investment adviser status under Rule 13d-1(b), with no intent to influence control and no single person's interest exceeding 5%. No changes in aggregate ownership levels are specified in the amendment.

  • Β·CUSIP for Apple Inc. common stock: 037833100
  • Β·As-of date referenced in filing: March 13, 2026

Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 13 filings

πŸ‡ΊπŸ‡Έ More from United States

View all β†’
S&P 500 Technology Sector SEC Filings β€” March 26, 2026 | Gunpowder Blog